Advanced search
Publication Cover
Biomarkers in Medicine Volume 13, 2019 - Issue 7
Submit an article Journal homepage
83
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Downregulation of Linc00515 in High-Grade Serous Ovarian Cancer and Its Relationship with Platinum Resistance

Mao-Wei Ni1 Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, PR China;2 Key Laboratory Diagnosis & Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, Zhejiang, PR ChinaView further author information
,
Jie Zhou3 Center for Medicinal Resources Research, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, Zhejiang, PR ChinaView further author information
,
Ying-Li Zhang4 Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, PR ChinaView further author information
,
Guo-Ming Zhou5 Laboratory Medicine, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, PR ChinaView further author information
,
Sheng-Jie Zhang1 Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, PR ChinaView further author information
,
Jian-Guo Feng1 Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, PR ChinaView further author information
,
Qiang Xu1 Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, PR ChinaView further author information
,
Yun Zhou1 Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, PR ChinaView further author information
,
Han-Zhou Mou1 Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, PR ChinaView further author information
&
Zhi-Guo Zheng1 Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, PR China;6 Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, Hangzhou, Zhejiang, PR ChinaCorrespondence[email protected]
View further author information
 show all
Pages 535-543 | Received 21 Oct 2018, Accepted 27 Feb 2019, Published online: 29 May 2019

References

  • Siegel RL , MillerKD, JemalAet al. Cancer statistics, 2018. CA Cancer J. Clin.68(1), 7–30 (2018).
  • Colombo PE , FabbroM, TheilletCet al. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit. Rev. Oncol. Hematol.89(2), 207–216 (2014).
  • Seidman JD , Horkayne-SzakalyI, HaibaMet al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int. J. Gynecol. Pathol.23(1), 41–44 (2004).
  • Basu M , MukhopadhyayS, ChatterjeeUet al. FGF16 promotes invasive behavior of SKOV-3 ovarian cancer cells through activation of mitogen-activated protein kinase (MAPK) signaling pathway. J. Biol. Chem.289(3), 1415–1428 (2014).
  • Perkel JM . Visiting “noncodarnia”. Biotechniques54(6), 301–304 (2013).
  • Bu D , YuK, SunSet al. NONCODE v3.0: integrative annotation of long noncoding RNAs. Nucleic Acids Res.40(Database issue), D210–D215 (2012).
  • Amaral PP , ClarkMB, GascoigneDKet al. lncRNAdb: a reference database for long noncoding RNAs. Nucleic Acids Res.39(Database issue), D146–D151 (2011).
  • Quek XC , ThomsonDW, MaagJLet al. lncRNAdb v2.0: expanding the reference database for functional long noncoding RNAs. Nucleic Acids Res.43(Database issue), D168–D173 (2015).
  • Prensner JR , IyerMK, SahuAet al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat. Genet.45(11), 1392–1398 (2013).
  • Gupta RA , ShahN, WangKCet al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature464(7291), 1071–1076 (2010).
  • Fan Y , ShenB, TanMet al. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J.281(7), 1750–1758 (2014).
  • Liu R , ZengY, ZhouCFet al. Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients. Sci. Rep.7(1), 18 (2017).
  • LINC00515 long intergenic non-protein coding RNA 515 [Homo sapiens (human)]. Gene ID: 282566 (2018). www.ncbi.nlm.nih.gov/gene/282566
  • Zheng ZG , XuH, SuoSSet al. The essential role of H19 contributing to cisplatin resistance by regulating glutathione metabolism in high-grade serous ovarian cancer. Sci. Rep.6, 26093 (2016).
  • Vajpeyi R . WHO classification of tumours: pathology and genetics of tumours of the breast and female genital organs. J. Clin. Pathol.58(6), 671–672 (2005).
  • Zeppernick F , Meinhold-HeerleinI. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch. Gynecol. Obstet.290(5), 839–842 (2014).
  • Fung-Kee-Fung M , OliverT, ElitLet al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr. Oncol.14(5), 195–208 (2007).
  • Du Bois A , LuckHJ, MeierWet al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst.95(17), 1320–1329 (2003).
  • Tian Z , WenS, ZhangYet al. Identification of dysregulated long non-coding RNAs/microRNAs/mRNAs in TNM I stage lung adenocarcinoma. Oncotarget8(31), 51703–51718 (2017).
  • Wang Y , LiebermanR, PanJet al. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol. Cancer.15(1), 70 (2016).
  • Mussnich P , RosaR, BiancoRet al. MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin. Ther. Targets19(8), 1017–1026 (2015).
  • Zhang M , LiuT, XiaBet al. Platelet-derived growth factor D is a prognostic biomarker and is associated with platinum resistance in epithelial ovarian cancer. Int. J. Gynecol. Cancer28(2), 323–331 (2018).
  • Zhang D , GaoJ, ZhuLet al. Chemoresistance is associated with MUC1 and Lewis y antigen expression in ovarian epithelial cancers. Int. J. Mol. Sci.14(6), 11024–11033 (2013).
  • Polterauer S , VergoteI, ConcinNet al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA–IV: analysis of the OVCAD data. Int. J. Gynecol. Cancer22(3), 380–385 (2012).
  • Eisenhauer EL , Abu-RustumNR, SonodaYet al. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol. Oncol.108(2), 276–281 (2008).
  • Berns EM , BowtellDD. The changing view of high-grade serous ovarian cancer. Cancer Res.72(11), 2701–2704 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.